CRSP News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CR

Mkt Cap

$4.76B

Volume

1.28M

Next Earnings

November 9th

Loading chart

CR

CRSPCRISPR Therapeutics AG

CRSP

Pay with—

Available Balance0.00

CR

Mkt Cap

$4.76B

Volume

1.28M

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to KnowCRISPR Therapeutics AG stock fell 4.48% on October 16, 2026, significantly underperforming the S&P 500's 1.09% decline. The stock has depreciated 10.13% over the past month, lagging the Medical sector's 2.68% gain. While analysts expect strong revenue growth of 1017.42% year-over-year for the upcoming quarter, the company maintains a Zacks Rank of #3 (Hold) with a slight 0.22% downward revision to consensus EPS estimates.Zacks Investment Research · Oct 16, 2026

Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical OfficerMatchpoint Therapeutics appointed John O'Malley, M.D., Ph.D., as Chief Medical Officer to lead clinical development of its pipeline of first-in-class oral small molecules for autoimmune and inflammatory diseases. The appointment follows the company's recent $150M Series B financing. Dr. O'Malley brings extensive immunology expertise from previous roles at CRISPR Therapeutics and Sanofi.GlobeNewswire Inc. · Oct 14, 2026

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential.The Motley Fool · Oct 13, 2026

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should KnowCRISPR Therapeutics AG (CRSP) declined 3.45% to $51.55, underperforming the S&P 500's 0.06% loss. Despite a 3.23% monthly gain, the stock faces headwinds. The company is expected to report an EPS of -$1.06 but projects significant revenue growth of 971.24% year-over-year. CRSP holds a Zacks Rank #2 (Buy) rating, though its industry ranks in the bottom 33% of all sectors.Zacks Investment Research · Oct 12, 2026

Roche Reports Positive Phase III Data on Eye Drug, FDA Accepts BLARoche announced encouraging one-year data from phase III studies showing vamikibart delivered sustained vision gains and reduced macular thickness in uveitic macular edema patients. The FDA accepted the drug's BLA with a decision expected by July 2027. If approved, vamikibart would be the first non-steroid targeted treatment for this sight-threatening condition. Roche is also advancing pipeline candidates including fenebrutinib for multiple sclerosis, sefaxersen for IgA nephropathy, and enicepatide for type 2 diabetes.Zacks Investment Research · Oct 12, 2026

Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending StockCRISPR Therapeutics (CRSP) has been trending on Zacks.com with shares returning +3.2% over the past month, outperforming the S&P 500's +2.4% gain. The company received a Zacks Rank #2 (Buy) rating based on stable earnings estimates and strong revenue growth forecasts (+971.2% for current quarter). However, the stock is trading at a premium valuation (F grade) compared to peers. The company is expected to turn profitable next fiscal year with EPS of $3.61.Zacks Investment Research · Oct 12, 2026

AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in CancerAbbVie announced that its investigational antibody-drug conjugate Temab-A (telisotuzumab adizutecan) has received two FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer. The designations were based on data from the M21-404 study, and the company is evaluating Temab-A across multiple advanced solid tumors as part of its expanding oncology pipeline.Zacks Investment Research · Oct 8, 2026

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost CashUltragenyx Pharmaceutical has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million following FDA approval of its gene therapy Genglycos. After a $42 million NIH payment obligation, approximately $168 million in non-dilutive capital will support the company's research, development, and commercialization efforts, helping it move toward profitability without equity financing.Zacks Investment Research · Oct 8, 2026

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You TradeCRISPR Therapeutics AG (CRSP) declined 5.82% to $54.00, underperforming the broader market gains. Despite a 2.78% monthly gain, the stock faces headwinds from its Medical sector's 4.26% loss. Upcoming earnings are expected to show an EPS of -$1.06 with significant revenue growth of 971.24% year-over-year, though the company maintains a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Oct 6, 2026

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should KnowCRISPR Therapeutics (CRSP) has attracted investor attention with significant revenue growth projections (+771.5% for current fiscal year) and improving earnings estimates. However, the company is rated Zacks Rank #3 (Hold) and trades at a premium valuation (F grade) compared to peers. The stock is expected to perform in line with the broader market in the near term.Zacks Investment Research · Sep 29, 2026

to start trading

CR

CRSPCRISPR Therapeutics AG

CRSP

Pay with—

Available Balance0.00

Your PositionYou don't own any CRSP yet.

Related Tickers

Earnings